Comparisons

Compounded Semaglutide vs Brand: Key Differences

GLP-1 Companion · 8 min read

The semaglutide shortage of 2022 through 2024 created a parallel market: hundreds of compounding pharmacies producing their own versions of semaglutide for patients who could not access brand Ozempic or Wegovy. At its peak, millions of Americans were obtaining compounded semaglutide through telehealth platforms. That era is now legally over in the United States following the FDA's February 2025 enforcement announcement. This article explains what compounding is, why it was permitted during the shortage, what changed, and why brand semaglutide is now the only recommended option.

What Is Drug Compounding?

Pharmaceutical compounding refers to the preparation of customized medications by licensed pharmacists for individual patients or in anticipation of patient need. Compounding has a legitimate and important role in medicine — for example, preparing a liquid version of a medication that is only commercially available as a tablet for a patient who cannot swallow pills, or mixing allergen-free formulations for patients with drug allergies. Compounding pharmacies in the United States operate under two regulatory frameworks:

• 503A pharmacies: Traditional compounding pharmacies that prepare medications for individual patients with a valid prescription. Regulated primarily by state pharmacy boards.
• 503B outsourcing facilities: Larger-scale compounding facilities registered with the FDA that can produce medications without patient-specific prescriptions (bulk compounding). Subject to FDA oversight and Current Good Manufacturing Practice (CGMP) standards.

Why Compounded Semaglutide Was Legal During the Shortage

Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are generally prohibited from producing copies of FDA-approved drugs that are commercially available. However, a critical exception applies: when a drug is listed on the FDA's drug shortage list, 503A pharmacies can compound copies of that drug, and 503B outsourcing facilities can compound it at scale.

Semaglutide — specifically both Ozempic and Wegovy — was added to the FDA's shortage list in 2022 as demand dramatically outpaced manufacturing capacity. This single administrative action opened the legal door for compounding pharmacies nationwide to produce semaglutide. Hundreds of pharmacies began offering compounded semaglutide, often paired with telehealth services, at prices dramatically lower than brand-name products.

The February 2025 FDA Announcement

On February 18, 2025, the FDA announced that semaglutide was no longer in shortage. Specifically, the agency concluded that both Ozempic (semaglutide for T2D) and Wegovy (semaglutide for obesity) were available in sufficient supply to meet demand. This announcement had immediate and significant legal consequences:

• Once removed from the shortage list, the compounding exemption that permitted production of semaglutide copies was no longer applicable
• The FDA gave 503B outsourcing facilities a wind-down period until March 2025 to stop bulk compounding semaglutide
• The FDA gave 503A traditional pharmacies until April 2025 to stop compounding semaglutide for individual prescriptions
• After those deadlines, compounding semaglutide for standard patients became illegal under federal law
• The FDA issued warning letters to multiple compounding facilities that continued producing semaglutide beyond the deadlines

Quality and Purity Risks of Compounded Semaglutide

Beyond the legal issues, the FDA and independent researchers documented significant quality concerns with compounded semaglutide throughout the shortage period. These concerns are relevant to understanding why the brand product is strongly preferred:

• Incorrect dosing: Compounded products were typically labeled in milligrams (mg) of semaglutide salt rather than the base form used in brand products. Since semaglutide acetate (the common compounded form) has a different molecular weight than semaglutide base, a "5 mg" compounded product did not contain the same active drug as a "5 mg" brand product.
• Semaglutide acetate vs semaglutide sodium vs semaglutide base: Different salt forms have not been independently tested for equivalent efficacy or safety; brand Ozempic/Wegovy uses semaglutide sodium.
• Lack of sterility testing: Many 503A pharmacies are not required to meet the same sterility assurance standards as pharmaceutical manufacturers.
• Contamination risks: FDA inspections of compounding facilities found multiple instances of contamination concerns, improper storage, and inadequate testing.
• Unapproved additives: Some compounded formulations contained additions like B12, vitamin C, or NAD+ that were not present in the clinical trial data and whose interactions with semaglutide have not been studied.
• No pharmacokinetic equivalence data: There is no published evidence that compounded semaglutide achieves the same blood concentration and receptor binding profile as the FDA-approved formulation.

Adverse Events Linked to Compounded Products

The FDA's MedWatch database received hundreds of reports of adverse events associated with compounded semaglutide during 2023 and 2024, including hospitalizations for severe nausea and vomiting at doses inconsistent with the brand titration schedule, suspected overdose events (attributable to dosing confusion between salt and base forms), and injection site infections. These reports informed the FDA's enforcement posture and their communication to consumers about compounded semaglutide risks.

What Patients Were Doing During the Shortage

The scale of compounded semaglutide use during the shortage period was enormous. Industry estimates suggest that as many as 1 to 2 million Americans were receiving compounded semaglutide through telehealth platforms at the peak in 2023 to 2024. Patients turned to compounding for several legitimate reasons:

• Brand Ozempic and Wegovy were genuinely unavailable at many pharmacies for extended periods
• Compounded semaglutide was substantially cheaper — often $150 to $300 per month vs $1,000+ for brand products
• Telehealth platforms made prescriptions more accessible without in-person visits
• Many patients who could not get their prescriptions filled saw compounding as their only realistic option

The clinical reality is that some patients on compounded semaglutide experienced genuine weight loss and diabetes improvement, while others experienced unexpected adverse effects or inadequate efficacy — outcomes that are difficult to disentangle from the quality variability inherent in compounded production.

Current Legal Status (April 2026)

As of April 2026, the legal status of compounded semaglutide in the United States is clear:

• Compounding semaglutide for standard weight loss or diabetes treatment is illegal under federal law
• The FDA has issued multiple warning letters and taken enforcement actions against compounding facilities that continued production
• Telehealth platforms that continued marketing compounded semaglutide after the FDA deadlines have faced regulatory and legal consequences
• The narrow exception for patients with documented allergies to brand product excipients remains, but requires specific medical justification and cannot be used as a general access pathway
• Tirzepatide (Mounjaro/Zepbound) shortage: A separate but related situation; as tirzepatide appeared on shortage lists in 2023-2024, compounding of tirzepatide followed a similar pattern. The FDA has been monitoring this separately.

Why Brand Semaglutide Is Strongly Recommended

• Proven manufacturing quality: Novo Nordisk's production facilities are held to FDA Current Good Manufacturing Practice standards with rigorous quality controls
• Clinical trial validation: Every dose and formulation of brand semaglutide was tested in large randomized controlled trials
• Established pharmacokinetics: The concentration-time profile, receptor binding, and metabolic effects of the brand product are fully characterized
• Regulatory oversight: Post-market surveillance, FDA adverse event reporting, and supply chain monitoring apply to brand products
• Legal status: Only brand products can legally be dispensed for semaglutide use in the United States as of February 2025
• Manufacturer savings programs: Brand Wegovy and Ozempic offer savings cards that bring monthly out-of-pocket costs to approximately $25 for eligible commercially insured patients

The shortage window that made compounded semaglutide a pragmatic patient choice has closed. Patients who were on compounded products should transition to brand semaglutide or discuss alternatives — including the newly available generic liraglutide (Saxenda equivalent) — with their healthcare provider.

What To Do If You Were on Compounded Semaglutide

• Speak with your prescribing provider about transitioning to brand Ozempic or Wegovy
• Check your insurance coverage: brand products may now be accessible through your plan with prior authorization
• Ask about the Novo Nordisk savings card program if you have commercial insurance
• If cost remains a barrier, discuss generic liraglutide 3.0 mg (available since August 2025) as an affordable alternative with a proven safety profile
• Do not continue purchasing from any source claiming to still legally produce compounded semaglutide — this is a red flag for regulatory non-compliance

The Bottom Line

Compounded semaglutide served a pragmatic role during a genuine drug shortage, but the FDA's February 2025 announcement closed that legal window definitively. Compounded semaglutide carries documented quality, purity, and dosing risks that brand products do not, and its production is now illegal in the United States for standard indications. Patients seeking semaglutide should use FDA-approved brand products (Ozempic or Wegovy), and those with cost concerns now have the option of generic liraglutide (Saxenda equivalent) as an affordable, rigorously tested alternative.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Wegovy (semaglutide) Prescribing Information. Novo Nordisk.